<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">AMIKACIN SULFATE</span><br/>(am-i-kay'sin)<br/><span class="topboxtradename">Amikin<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">aminoglycoside antibiotic</span><br/><b>Prototype: </b>Gentamicin<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>250 mg/mL, 50 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Semisynthetic derivative of kanamycin with broad range of antimicrobial activity that includes many strains resistant to other
         aminoglycosides. Pharmacologic properties are essentially the same as those of gentamicin. Appears to inhibit protein synthesis
         in bacterial cell and is usually bactericidal.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Effective against a wide variety of gram-negative bacteria including <i>Escherichia coli, Enterobacter, Klebsiella pneumoniae,</i> most strains of <i>Pseudomonas aeruginosa,</i> and many strains of <i>Proteus species, Serratia, Providencia stuartii, Citrobacter freundii, Acinetobacter.</i> Also effective against penicillinase- and non-penicillinase-producing <i>Staphylococcus</i> species, and against <i>Mycobacterium tuberculosis</i> and atypical mycobacteria.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Primarily for short-term treatment of serious infections of respiratory tract, bones, joints, skin, and soft tissue, CNS (including
         meningitis), peritonitis burns, recurrent urinary tract infections (UTIs).
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Intrathecal or intraventricular administration, in conjunction with IM or IV dosage.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>History of hypersensitivity or toxic reaction with an aminoglycoside antibiotic. Safety during pregnancy (category C), lactation,
         neonates and infants, or use period exceeding 14 d is not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Impaired renal function; eighth cranial (auditory) nerve impairment; preexisting vertigo or dizziness, tinnitus, or dehydration;
         fever; older adults, premature infants, neonates and infants; myasthenia gravis; parkinsonism; hypocalcemia.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Moderate to Severe Infections</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV/IM</span> 57.5 mg/kg loading dose, then 7.5 mg/kg q12h<br/><span class="rdage">Child:</span> <span class="rdroute">IV/IM</span> 57.5 mg/kg loading dose, then 5 mg/kg q8h or 7.5 mg/kg q12h<br/><span class="rdage">Neonate:</span> <span class="rdroute">IV/IM</span> 10 mg/kg loading dose, then 7.5 mg/kg q1224h<br/><br/><span class="indicationtitle">Uncomplicated UTI</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV/IM</span> 250 mg q12h<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Use the 250 mg/mL vials for IM injection. Calculate the required dose and withdraw the equivalent number of mLs from the vial.</li>
<li>Give deep IM into a large muscle.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><ul>
<li>Verify correct IV concentration and rate of infusion with physician for neonates, infants, and children.</li>
</ul>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype">Intermittent:</span>  Add contents of 500 mg vial to 100 or 200 mL D5W, NS injection, or other diluent recommended by manufacturer. For pediatric patients, volume of diluent depends on patient's fluid tolerance. 
                  								Note: Color of solution may vary from colorless to light straw color or very pale yellow. Discard solutions that appear discolored
                  or that contain particulate matter.
                  							 
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Intermittent:</span>  Give a single adult dose (including loading dose) over at least 3060 min by IV infusion. Increase infusion time to 12 h for infants. Monitor drip rate carefully. A rapid rise in serum amikacin level can cause respiratory depression (neuromuscular blockade)
                  and other signs of toxicity. 
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span>
<b>Aminophylline,</b>
<b>amphotericin B,</b>
<span class="classification">cephalosporins</span>, <b>chlorothiazide,</b>
<b>erythromycin,</b>
<b>heparin,</b>
<b>oxytetracycline,</b>
<span class="classification">penicillins</span>, <b>phenytoin,</b>
<b>thiopental,</b>
<b>vitamin B complex with C,</b>
<b>warfarin.</b>
<span class="incompattype">Y-site:</span>
<b>Amphotericin B,</b>
<b>azithromycin, heparin,</b>
<b>phenytoin,</b>
<b>thiopental.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Store at 15°30° C (59°86° F) unless otherwise directed.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Neurotoxicity: drowsiness, unsteady gait, weakness, clumsiness, paresthesias, tremors, convulsions, peripheral neuritis. <span class="typehead">Special Senses:</span>
<span class="speceff-common">Auditoryototoxicity,</span> high-frequency hearing loss, complete hearing loss (occasionally permanent); tinnitus; ringing or buzzing in ears; <span class="speceff-common">Vestibular:</span> dizziness, ataxia. <span class="typehead">GI:</span> Nausea, vomiting, <span class="speceff-life">hepatotoxicity</span>. <span class="typehead">Metabolic:</span> Hypokalemia, hypomagnesemia. <span class="typehead">Skin:</span> Skin rash, urticaria, pruritus, redness. <span class="typehead">Urogenital:</span> Oliguria, urinary frequency, hematuria, <span class="speceff-life">tubular necrosis</span>, azotemia. <span class="typehead">Other:</span> Superinfections. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<span class="classification">anesthetics</span>, <span class="classification">skeletal muscle relaxants</span> have additive neuromuscular blocking effects; <b>acyclovir,</b>
<b>amphotericin B,</b>
<b>bacitracin,</b>
<b>capreomycin,</b>
<b>cephalosporins,</b>
<b>colistin,</b>
<b>cisplatin,</b>
<b>carboplatin,</b>
<b>methoxyflurane,</b>
<b>polymyxin B,</b>
<b>vancomycin,</b>
<b>furosemide,</b>
<b>ethacrynic acid</b> increase risk of ototoxicity and nephrotoxicity. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Peak:</span> 30 min IV; 45 min to 2 h IM. <span class="typehead">Distribution:</span> Does not cross bloodbrain barrier; crosses placenta; accumulates in renal cortex. <span class="typehead">Elimination:</span> 9498% excreted renally in 24 h, remainder in 1030 d. <span class="typehead">Half-Life:</span> 23 h in adults, 48 h in neonates. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Baseline tests: Before initial dose, C&amp;S; renal function and vestibulocochlear nerve function (and at regular intervals during
            therapy; closely monitor in the older adult, patients with documented ear problems, renal impairment, or during high dose
            or prolonged therapy).
         </li>
<li>Monitor peak and trough amikacin blood levels: Draw blood 1 h after IM or immediately after completion of IV infusion; draw
            trough levels immediately before the next IM or IV dose.
         </li>
<li>Lab tests: Periodic serum creatinine and BUN, complete urinalysis. With treatment over 10 d, daily tests of renal function,
            weekly audiograms, and vestibular tests are strongly advised.
         </li>
<li>Monitor serum creatinine or creatinine clearance (generally preferred) more often, in the presence of impaired renal function,
            in neonates, and in the older adult; note that prolonged high trough (&gt;8 mcg/mL) or peak (&gt;3035 mcg/mL) levels are associated
            with toxicity.
         </li>
<li>Monitor S&amp;S of ototoxicity [primarily involves the cochlear (auditory) branch; high-frequency deafness usually appears first
            and can be detected only by audiometer]; indicators of declining renal function; respiratory tract infections and other symptoms
            indicative of superinfections and notify physician should they occur.
         </li>
<li>Monitor for and report auditory symptoms (tinnitus, roaring noises, sensation of fullness in ears, hearing loss) and vestibular
            disturbances (dizziness or vertigo, nystagmus, ataxia).
         </li>
<li>Monitor &amp; report any changes in I&amp;O, oliguria, hematuria, or cloudy urine. Keeping patient well hydrated reduces risk of nephrotoxicity;
            consult physician regarding optimum fluid intake.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report immediately any changes in hearing or unexplained ringing/roaring noises or dizziness, and problems with balance or
            coordination.
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>